#### **AMENDMENTS**

# **Listing of claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Claims 1-6 (Cancelled)

7. (Currently amended) A composition for targeting double stranded nucleic acids, said composition comprising a pharmaceutically acceptable carrier and an effective amount of a padlock probe oligonucleotide having two free nucleic acid end parts which are at least partially complementary to and capable of hybridizing with at least substantially neighboring respective regions of a double stranded target nucleic acid so that the padlock probe can be circularized by joining said free end parts to thereby catenate with [[the]] said target sequence nucleic acid, wherein said target sequence nucleic acid is directly inhibited and wherein said composition does not contain said target nucleic acid.

## 8. (Cancelled)

- 9. (**Previously amended**) The composition according to Claim 7, further comprising a linking agent, wherein said linking agent is capable of joining said two free nucleic acid end parts.
- 10. **(Previously amended)** The composition according to Claim 9, wherein said linking agent is a ligase enzyme.

### 11. (Cancelled)

12. (**Currently Amended**) The composition according to any one of Claims 7, 9, or 10[[, or 11]] wherein said padlock probe comprises a non-natural nucleic acid <del>or polymer</del>.